← All trials
NCT05044364
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 11, 2021
- Primary completion
- Apr 1, 2022
- Completion date
- Oct 10, 2022
- First posted
- Sep 14, 2021
- Last posted
- Sep 14, 2021
- Enrollment
- 10
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shenzhen UniversityLead sponsor
- Shenzhen UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.